Replies to post #149302 on Biotech Values

[apljack]

Bladerunner,

I don't know what happened at the FDA, but I do know the potential activity of Ampakines. The problem with the drug (at least the one I was involved with research wise, CX 516) were the consistent psychotic-like side effects of the drug and the seeming downplay of the side effects by COR. When confronted by patients who reported the unpleasant side effects to a significant degree then have the study abruptly stopped without identifying the problem, left investors without the information necessary for an investment, IMO, which is why many lost alot of money and fits the definition of scam, in my book. Then to have the co. continue to promulgate study after study without usable results, seemed to me to be an exercise in futility and way for corporate insiders to make money, keep their jobs, and fleece the investing public by stringing them on.